21 completed, 7 recruiting, 6 not yet recruiting, 4 terminated. 44 Phase 2, 6 Phase 3, 1 Phase 1.
Follow Pyrazinamide: new trials by email Literature Review of Pyrazinamide trials Research Report on Pyrazinamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2027-02-01 | 2026-11-02 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | TASK Applied Science | 135 | 2026-09-25 | 2026-09-25 |
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg - Pulmonary Tuberculosis (TB) | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 80 | 2026-01-03 | 2026-01-23 |
| Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis RESP30TB, HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) - Pulmonary Tuberculoses | Phase 2 | Recruiting | Thirty Respiratory Limited | 24 | 2025-10-13 | 2026-01-12 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis Rifampin, Isoniazid, Rifapentine (RPT) - Mild Spinal Tuberculosis | Phase 2 | Not yet recruiting | Shandong University | 300 | 2025-04-05 | 2025-04-08 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 341 | 2025-03-11 | 2026-11-02 |
| A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based - Tuberculosis | Phase 2 | Recruiting | TASK Applied Science | 60 | 2025-03-03 | 2025-03-07 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD) - Tuberculous Meningitis | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 330 | 2023-12-07 | 2026-06-02 |
| Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA) - Tuberculosis, Pulmonary, HIV | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 94 | 2023-11-24 | 2026-08-05 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| PanACEA - STEP2C -01 BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Recruiting | Michael Hoelscher | 390 | 2023-04-14 | 2025-10-07 |
| Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide rifampicin, pyrazinamide, HRZE - Tuberculosis, Pulmonary | Phase 2 | Suspended | University Hospital, Linkoeping | 40 | 2022-11-30 | 2026-08-17 |
| Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) Isoniazid, Rifampicin, Ethambutol - Tuberculosis, Pulmonary Tuberculosis | Phase 2 | Completed | University of Massachusetts, Worcester | 112 | 2022-03-04 | 2026-08-06 |
Showing 20 of 44. Sign in to see all of them.
Tuberculosis, Pulmonary (30) · Tuberculosis (29) · Tuberculosis, Multidrug-Resistant (6) · HIV Infections (4) · Extensively Drug-Resistant Tuberculosis (2) · Acquired Immunodeficiency Syndrome (1) · Central Nervous System Diseases (1) · Gram-Positive Bacterial Infections (1) · Latent Tuberculosis (1) · Tuberculosis, Meningeal (1)
Global Alliance for TB Drug Development (7) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Centers for Disease Control and Prevention (3) · Michael Hoelscher (3) · Obafemi Awolowo University Teaching Hospital (3) · TASK Applied Science (3) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2) · Johns Hopkins University (2) · University College, London (2) · Brigham and Women's Hospital (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Gates Medical Research Institute (1) · Ministry of Health, Saudi Arabia (1) · National University Hospital, Singapore (1) · Seoul National University Hospital (1)
South Africa (30) · Uganda (12) · Tanzania (9) · Philippines (8) · Brazil (7) · Haiti (6) · Vietnam (6) · India (5) · Malawi (5) · Peru (5) · Kenya (4) · Thailand (4) · Zimbabwe (4) · Canada (3) · Georgia (3)
Bolanle A Omotoso, MD (3) · Nicholas Paton (2) · Olanisun O Adewole, MD (2) · Richard E Chaisson, MD (2) · Susan Dorman, MD (2) · Andreas Diacon (1) · Andreas Diacon, MD (1) · Andreas Diacon, MD, PhD (1) · Andreas Diacon, Prof (1) · Anthony Garcia-Prats, MD, MSc, PhD (1) · Antonio Lombardi, MD (1) · Clifton E Barry, Ph.D. (1) · Constance A Benson, MD (1) · Daniel W Fitzgerald, MD (1)
PMID 33542052, PMID 36808186, PMID 38768617, PMID 16675781, PMID 19406981, PMID 21494548, PMID 22828481, PMID 23433590, PMID 24663014, PMID 25622149, PMID 25795076, PMID 27159505, PMID 27550361, PMID 28100438, PMID 28739794, PMID 29528048, PMID 30102705, PMID 30651149, PMID 31732485, PMID 31932382, PMID 33229425, PMID 33834177, PMID 35175905, PMID 35273049, PMID 35315690, PMID 36455068, PMID 36522208, PMID 36966799, PMID 39622823, PMID 39651910, PMID 39793592, PMID 40195983, PMID 40414233, PMID 40817073, PMID 40915311, PMID 40915316, PMID 41487489, PMID 41510291, PMID 41616265, PMID 42560062, PMID 42568101
U01AI068636 (2), 2019 (1), U01AI134585 (1), U01AI170426 (1), U01AI192041 (1)